Acuta Capital Partners’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Acuta Capital Partners’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-55,000	Closed	-$1.3M	–	51
2019 Q3	$1.3M	Buy	+55,000	New	+$1.63M	0.94%	23
2018 Q2	–	Sell	-270,000	Closed	-$1.43M	–	83
2018 Q1	$1.43M	Buy	+270,000	New	+$1.93M	0.23%	40
2017 Q4	–	Sell	-71,500	Closed	-$1.04M	–	93
2017 Q3	$1.04M	Sell	71,500 -302,007	-81%	-$4.57M	0.19%	51
2017 Q2	$7M	Buy	373,507 +125,551	+51%	+$2.83M	1.96%	14
2017 Q1	$5.28M	Sell	247,956 -129,953	-34%	-$2.48M	1.25%	22
2016 Q4	$5.74M	Buy	+377,909	New	+$5.14M	2.13%	18

Other funds holding RARX

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acuta Capital Partners's RARX Position: Q4 2019 in Review

Acuta Capital Partners sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q4 2019, closing a stake of 55,000 shares — an estimated $1.3M sold.

Acuta Capital Partners first reported a position in RARX in Q4 2016 and held it in 6 quarters. The position peaked at $7M in Q2 2017. 146 funds tracked by Wall St. Rank hold RARX as of Q4 2019.

Acuta Capital Partners reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Acuta Capital Partners sold 55,000 Ra Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $1.3M.
Acuta Capital Partners first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 6 quarters.
Acuta Capital Partners's Ra Pharmaceuticals, Inc. Common Stock position peaked at $7M in Q2 2017.
146 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on Acuta Capital Partners's 13F filing for Q4 2019, filed 14 Feb 2020.